Latest Repros Therapeutics Inc (RPRX) Headlines
Post# of 35
Posted On: 03/13/2014 1:28:26 PM
Latest Repros Therapeutics Inc (RPRX) Headlines
Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2013 Financial Results
GlobeNewswire - Thu Mar 13, 8:15AM CDT
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced financial results for the fourth quarter and year ended December 31, 2013.
Bullish Two Hundred Day Moving Average Cross - RPRX
MarketNewsVideo.com - Tue Feb 18, 3:38PM CST
In trading on Tuesday, shares of Repros Therapeutics Inc crossed above their 200 day moving average of $19.54, changing hands as high as $19.87 per share. Repros Therapeutics Inc shares are currently trading up about 6% on the day.
Data on Repros' Androxal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 5:26PM CST
Repros Therapeutics recently released additional results from its phase III study, ZA-300, on candidate Androxal.
Repros Therapeutics (RPRX) Jumps: Stock Rises 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 8:46AM CST
Repros Therapeutics was a big mover last session, with shares rising over 6%.
Repros Reports Findings From the Six Month Study of Androxal(R) in Men With Secondary Hypogonadism
GlobeNewswire - Mon Feb 10, 8:39AM CST
-- Greater Than 80% of Men Obtained T in the Normal Range
This Week in Biotech: Sunny, With No Chance of Rain
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 08, 1:05PM CST
With the SPDR S&P Biotech Index up 57% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
Repros Shares Soar After FDA Meeting - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 9:27AM CST
Share price of Repros surged 15.8% after its meeting with the FDA on Androxal
Biotech Winners: Pernix, Myriad, Repros, OraSure
David Williamson and Max Macaluso, The Motley Fool - Motley Fool - Thu Feb 06, 7:40PM CST
In this video from Thursday's Market Checkup , Motley Fool health-care analysts David Williamson and Max Macaluso dive into the biggest stories impacting health-care investors on the market today. In this segment, a look at some big winners during...
Nasdaq stocks posting largest percentage increases
AP - Thu Feb 06, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Repros Therapeutics, Inc. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 06, 2:11PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Repros Therapeutics , a clinical-stage...
Repros Therapeutics rises on Androxal update
AP - Thu Feb 06, 10:35AM CST
NEW YORK (AP) — Shares of Repros Therapeutics jumped Thursday after the company said it doesn't think it will have to run additional safety studies of its testosterone drug Androxal.
Repros Meets With FDA to Discuss Data Requirements for Androxal(R) in the Treatment of Secondary Hypogonadism
GlobeNewswire - Wed Feb 05, 11:22PM CST
-- NDA submission remains anticipated by year end 2014
Analysis of the Southeast Asian Manufacturing Execution Systems Market
PR Newswire - Thu Jan 30, 6:14AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:
Uptrend Call Working As Repros Therapeutics Stock Rises 18.8% (RPRX)
Comtex SmarTrend(R) - Thu Jan 23, 9:49AM CST
SmarTrend identified an Uptrend for Repros Therapeutics (NASDAQ:RPRX) on December 19th, 2013 at $18.48. In approximately 1 month, Repros Therapeutics has returned 18.78% as of today's recent price of $21.95.
Repros Therapeutics Up 17.2% Since SmarTrend Uptrend Call (RPRX)
Comtex SmarTrend(R) - Thu Jan 16, 9:27AM CST
SmarTrend identified an Uptrend for Repros Therapeutics (NASDAQ:RPRX) on December 19th, 2013 at $18.48. In approximately 4 weeks, Repros Therapeutics has returned 17.15% as of today's recent price of $21.65.
Can the Rally in Repros Therapeutics (RPRX) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 5:43AM CST
Can the Rally in Repros Therapeutics (RPRX) Shares Continue?
Pre-Market Pulse: Dendreon, Novartis AG, Stryker, and Repros Therapeutics
PR Newswire - Wed Jan 15, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Repros Continues to Gain on Androxal News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 4:00PM CST
Repros has initiated two studies on its secondary hypogonadism candidate, Androxal.
Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2013 Financial Results
GlobeNewswire - Thu Mar 13, 8:15AM CDT
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced financial results for the fourth quarter and year ended December 31, 2013.
Bullish Two Hundred Day Moving Average Cross - RPRX
MarketNewsVideo.com - Tue Feb 18, 3:38PM CST
In trading on Tuesday, shares of Repros Therapeutics Inc crossed above their 200 day moving average of $19.54, changing hands as high as $19.87 per share. Repros Therapeutics Inc shares are currently trading up about 6% on the day.
Data on Repros' Androxal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 5:26PM CST
Repros Therapeutics recently released additional results from its phase III study, ZA-300, on candidate Androxal.
Repros Therapeutics (RPRX) Jumps: Stock Rises 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 8:46AM CST
Repros Therapeutics was a big mover last session, with shares rising over 6%.
Repros Reports Findings From the Six Month Study of Androxal(R) in Men With Secondary Hypogonadism
GlobeNewswire - Mon Feb 10, 8:39AM CST
-- Greater Than 80% of Men Obtained T in the Normal Range
This Week in Biotech: Sunny, With No Chance of Rain
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 08, 1:05PM CST
With the SPDR S&P Biotech Index up 57% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
Repros Shares Soar After FDA Meeting - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 9:27AM CST
Share price of Repros surged 15.8% after its meeting with the FDA on Androxal
Biotech Winners: Pernix, Myriad, Repros, OraSure
David Williamson and Max Macaluso, The Motley Fool - Motley Fool - Thu Feb 06, 7:40PM CST
In this video from Thursday's Market Checkup , Motley Fool health-care analysts David Williamson and Max Macaluso dive into the biggest stories impacting health-care investors on the market today. In this segment, a look at some big winners during...
Nasdaq stocks posting largest percentage increases
AP - Thu Feb 06, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Repros Therapeutics, Inc. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 06, 2:11PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Repros Therapeutics , a clinical-stage...
Repros Therapeutics rises on Androxal update
AP - Thu Feb 06, 10:35AM CST
NEW YORK (AP) — Shares of Repros Therapeutics jumped Thursday after the company said it doesn't think it will have to run additional safety studies of its testosterone drug Androxal.
Repros Meets With FDA to Discuss Data Requirements for Androxal(R) in the Treatment of Secondary Hypogonadism
GlobeNewswire - Wed Feb 05, 11:22PM CST
-- NDA submission remains anticipated by year end 2014
Analysis of the Southeast Asian Manufacturing Execution Systems Market
PR Newswire - Thu Jan 30, 6:14AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:
Uptrend Call Working As Repros Therapeutics Stock Rises 18.8% (RPRX)
Comtex SmarTrend(R) - Thu Jan 23, 9:49AM CST
SmarTrend identified an Uptrend for Repros Therapeutics (NASDAQ:RPRX) on December 19th, 2013 at $18.48. In approximately 1 month, Repros Therapeutics has returned 18.78% as of today's recent price of $21.95.
Repros Therapeutics Up 17.2% Since SmarTrend Uptrend Call (RPRX)
Comtex SmarTrend(R) - Thu Jan 16, 9:27AM CST
SmarTrend identified an Uptrend for Repros Therapeutics (NASDAQ:RPRX) on December 19th, 2013 at $18.48. In approximately 4 weeks, Repros Therapeutics has returned 17.15% as of today's recent price of $21.65.
Can the Rally in Repros Therapeutics (RPRX) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 5:43AM CST
Can the Rally in Repros Therapeutics (RPRX) Shares Continue?
Pre-Market Pulse: Dendreon, Novartis AG, Stryker, and Repros Therapeutics
PR Newswire - Wed Jan 15, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Repros Continues to Gain on Androxal News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 4:00PM CST
Repros has initiated two studies on its secondary hypogonadism candidate, Androxal.
(0)
(0)